Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

詳細記述

保存先:
書誌詳細
出版年:J Oncol
主要な著者: Chauhan, Aman, Farooqui, Zainab, Murray, Le Aundra, Weiss, Heidi L., War Myint, Zin, Raajasekar, Arun Kumar A., Evers, B. Mark, Arnold, Susanne, Anthony, Lowell
フォーマット: Artigo
言語:Inglês
出版事項: Hindawi 2018
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5964580/
https://ncbi.nlm.nih.gov/pubmed/29853889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3519247
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料